Bank of New York Mellon Corp Has $41,000 Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Bank of New York Mellon Corp cut its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 93.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,086 shares of the company’s stock after selling 155,231 shares during the quarter. Bank of New York Mellon Corp owned 0.13% of Karyopharm Therapeutics worth $41,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Velan Capital Investment Management LP acquired a new stake in Karyopharm Therapeutics in the fourth quarter valued at approximately $27,000. Focus Partners Wealth bought a new position in Karyopharm Therapeutics in the 4th quarter worth about $31,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth $32,000. Two Sigma Advisers LP increased its position in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP purchased a new position in Karyopharm Therapeutics in the fourth quarter worth $85,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Stock Up 3.9%

KPTI stock opened at $4.03 on Thursday. The stock has a market capitalization of $34.82 million, a price-to-earnings ratio of -0.30 and a beta of 0.28. Karyopharm Therapeutics Inc. has a twelve month low of $3.51 and a twelve month high of $16.95. The firm’s fifty day simple moving average is $4.34 and its two-hundred day simple moving average is $5.90.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, May 12th. The company reported ($2.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.21) by $1.44. The company had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $35.12 million. As a group, equities research analysts expect that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on KPTI shares. HC Wainwright cut Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 16th. Robert W. Baird cut their price target on Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Royal Bank Of Canada lowered their price objective on Karyopharm Therapeutics from $34.00 to $33.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Barclays raised their price target on Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 13th. Finally, Wall Street Zen lowered Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.40.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).